AC
BCTXL

Armistice Capital’s BriaCell Therapeutics Warrant BCTXL Stock Holding History

Armistice Capital’s Portfolio BCTXL Stock Details BCTXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$478K Hold
536,600
– – 0.01% 217
2026
Q1 		$553K Buy
+536,600
New +$568K 0.01% 171

Other funds holding BCTXL

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
MA
MYDA Advisors Woodmere, New York $672M AUM 71.14% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $551M AUM 34.68% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

Armistice Capital's BCTXL Position: Q2 2026 in Review

Armistice Capital held its BriaCell Therapeutics Warrant (BCTXL) position steady in Q2 2026 at 536,600 shares worth $478K. The position accounts for 0.01% of the portfolio, ranked #217.

Armistice Capital first reported a position in BCTXL in Q1 2026 and has held it in 2 quarters since. The position peaked at $553K in Q1 2026. 10 funds tracked by Wall St. Rank hold BCTXL as of Q2 2026.

  • Armistice Capital held 536,600 shares of BriaCell Therapeutics Warrant worth $478K as of Q2 2026.
  • Armistice Capital left its BriaCell Therapeutics Warrant share count unchanged in Q2 2026.
  • BriaCell Therapeutics Warrant made up 0.01% of Armistice Capital's portfolio in Q2 2026, its #217 holding.
  • Armistice Capital first reported a position in BriaCell Therapeutics Warrant in Q1 2026 and has held it in 2 quarters since.
  • Armistice Capital's BriaCell Therapeutics Warrant position peaked at $553K in Q1 2026.
  • 10 funds tracked by Wall St. Rank held BriaCell Therapeutics Warrant as of Q2 2026.

Based on Armistice Capital's 13F filing for Q2 2026, filed 14 Aug 2026.